Relevant bibliographies by topics / Erectile dysfunction drugs / Journal articles
To see the other types of publications on this topic, follow the link: Erectile dysfunction drugs.

Journal articles on the topic 'Erectile dysfunction drugs'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Erectile dysfunction drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Greener, Mark. "Erectile dysfunction drugs." Inpharma Weekly &NA;, no. 1203 (September 1999): 3–4. http://dx.doi.org/10.2165/00128413-199912030-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Terzic, Branka, Srdjan Markovic, Jelena Grujic, and Ljiljana Djukic. "Cardiovascular drugs and erectile dysfunction." Hospital Pharmacology - International Multidisciplinary Journal 1, no. 3 (2014): 174–79. http://dx.doi.org/10.5937/hpimj1403174t.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Saffon Cuartas, José Pablo, Carolina Sandoval-Salinas, Juan M. Martínez, and Héctor A. Corredor. "Treatment of Priapism Secondary to Drugs for Erectile Dysfunction." Advances in Urology 2019 (August 22, 2019): 1–4. http://dx.doi.org/10.1155/2019/6214921.

Full text
Abstract:
Priapism may present as a side effect in patients treated with medications for erectile dysfunction, in which it should be controlled in a timely manner to avoid complications. There is little information regarding the use of local measures for the treatment of this condition. This study was done with the objective to describe the management of priapism secondary to erectile dysfunction drugs in a cohort of men. Records of emergencies and adverse events were reviewed by two researchers to identify patients diagnosed with erectile dysfunction who received oral or intracavernosal drugs for their illness and presented priapism. Sociodemographic data, clinical background, and information on the duration, management, and evolution of the priapism were extracted. Priapism incidence, percentage of improvement by type of treatment subgroups, and frequency of complications were estimated. 698 patients were treated with PDE-5 inhibitors and 2,135 with intracavernosal drugs. Thirty-one patients (1.4%) reported at least one priapism event during treatment, all with intracavernosal drugs. Treatment with local measures was effective for 10 (32.2%) patients, 1 (3.2%) required terbutaline, 19 (61.2%) used intracavernosal etilefrine, and 1 (3.2%) required drainage and flushing of cavernous bodies. After the priapism episode, 3 (9.6%) patients required an increased dose of the drug in order to achieve satisfactory erection. The results suggest that in men treated for priapism secondary to the use of sexual impotence drugs, initial treatment with local measures and etilefrine can achieve detumescence, decreasing the need for invasive procedures or surgery as a first-line therapy alternative. It is necessary to carry out research studies to confirm this hypothesis.
APA, Harvard, Vancouver, ISO, and other styles
4

MONTORSI, F. "WS027 Oral drugs for erectile dysfunction." Journal of the European Academy of Dermatology and Venereology 9 (September 1997): S84. http://dx.doi.org/10.1016/s0926-9959(97)89186-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Belavic, Jennifer M. "A look at erectile dysfunction drugs." Nursing Made Incredibly Easy! 8, no. 1 (January 2010): 13–15. http://dx.doi.org/10.1097/01.nme.0000366095.77674.c5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

EISENBERG, JEFFREY S. "CVD Drugs, Lifestyle Fix Erectile Dysfunction." Internal Medicine News 44, no. 16 (October 2011): 48. http://dx.doi.org/10.1016/s1097-8690(11)70841-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hornbrook, M. C., and J. Holup. "Insurance Coverage for Erectile Dysfunction Drugs." Clinical Pharmacology & Therapeutics 89, no. 1 (January 2011): 19–21. http://dx.doi.org/10.1038/clpt.2010.265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Turkoski, Beatrice B. "Drugs Used to Treat Erectile Dysfunction." Orthopaedic Nursing 27, no. 3 (May 2008): 201–4. http://dx.doi.org/10.1097/01.nor.0000320552.30020.7b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Drugs Used to Treat Erectile Dysfunction." Orthopaedic Nursing 27, no. 3 (May 2008): 205–6. http://dx.doi.org/10.1097/01.nor.0000320553.07149.6d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blanker, Marco H., and Arianne P. Verhagen. "Lipid-lowering drugs and erectile dysfunction." Family Practice 19, no. 5 (October 2002): 567. http://dx.doi.org/10.1093/fampra/19.5.567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Briganti, Alberto, Andrea Salonia, Andrea Gallina, Nazareno Suardi, Patrizio Rigatti, and Francesco Montorsi. "Emerging oral drugs for erectile dysfunction." Expert Opinion on Emerging Drugs 9, no. 1 (May 2004): 179–89. http://dx.doi.org/10.1517/14728214.9.1.179.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Verit, Ayhan, and Halit Oguz. "Ophthalmic Aspects of Erectile Dysfunction Drugs." American Journal of Ophthalmology 141, no. 3 (March 2006): 598. http://dx.doi.org/10.1016/j.ajo.2005.10.051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Nedogoda, S. V., A. S. Salasyuk, I. N. Barykina, A. A. Ledyaeva, V. V. Tsoma, and E. V. Chumachek. "Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction." CardioSomatics 4, no. 2 (June 15, 2013): 57–66. http://dx.doi.org/10.26442/cs45034.

Full text
Abstract:
Objective: to evaluate the antihypertensive efficacy and effect of nebivolol and valsartan on metabolic parameters and erective function in patients with hypertension, metabolic syndrome, and erectile dysfunction. Subjects and methods. A 12-week randomized, blind, controlled, parallel-group, comparative (nebivolol versus valsartan) trial enrolled 40 patients with hypertension, metabolic syndrome, and erectile dysfunction. Results. There were no significant differences between the drugs in their antihypertensive efficiency. Nebivolol exerted a more pronounced positive effect on cardioand angioprotection and lipid and carbohydrate metabolic parameters. It had no negative effect on metabolic parameters. Therapy with nebivolol versus valsartan produced a pronounced positive effect on blood androgen levels and erectile function. Moreover, the quality-of-life indicators also showed a significant improvement in the nebivolol group. Evaluation of the tolerability and adverse reactions of the drugs demonstrated no side effects in both groups.
APA, Harvard, Vancouver, ISO, and other styles
14

Sakakibara, Ryuji, Masahiko Kishi, Emina Ogawa, Fuyuki Tateno, Tomoyuki Uchiyama, Tatsuya Yamamoto, and Tomonori Yamanishi. "Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease." Parkinson's Disease 2011 (2011): 1–21. http://dx.doi.org/10.4061/2011/924605.

Full text
Abstract:
Bladder dysfunction (urinary urgency/frequency), bowel dysfunction (constipation), and sexual dysfunction (erectile dysfunction) (also called “pelvic organ” dysfunctions) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, pelvic organ autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, peripheral myenteric pathology causing slowed colonic transit (loss of rectal contractions) and central pathology causing weak strain and paradoxical anal sphincter contraction on defecation (PSD, also called as anismus) are responsible for the bowel dysfunction. In addition, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine-oxytocin pathways, which normally promote libido and erection. The pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Dietary fibers, laxatives, and “prokinetic” drugs such as serotonergic agonists are used to treat bowel dysfunction in PD. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life.
APA, Harvard, Vancouver, ISO, and other styles
15

Dündar, Sema Oruç. "Visual loss associated with erectile dysfunction drugs." Canadian Journal of Ophthalmology 42, no. 1 (February 2007): 10–12. http://dx.doi.org/10.3129/can.j.ophthalmol.06-122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Seftel, Allen D. "Re: Insurance Coverage for Erectile Dysfunction Drugs." Journal of Urology 185, no. 5 (May 2011): 1838. http://dx.doi.org/10.1016/s0022-5347(11)60221-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

WEEKS, BRIDGET, and CARMEL T. FICORELLI. "How new drugs help treat erectile dysfunction." Nursing 36, no. 1 (January 2006): 18–19. http://dx.doi.org/10.1097/00152193-200601000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Weeks, Bridget, and Carmel T. Ficorelli. "Treating erectile dysfunction without first-line drugs." Nursing 36, no. 3 (March 2006): 26–27. http://dx.doi.org/10.1097/00152193-200603000-00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Vendeira, Pedro, Carla Costa, and Ronald Virag. "Diabetes-associated Erectile Dysfunction." European Endocrinology 05 (2009): 75. http://dx.doi.org/10.17925/ee.2009.05.00.75.

Full text
Abstract:
Erectile dysfunction (ED) is a common complication of diabetes, with a prevalence ranging from 15 to 55%. The basis underlying diabetesassociated ED is multifactorial, involving changes in peripheral nerve activity and alterations in endothelial cell function. Due to the complexity of this pathology, the development of experimental models has been crucial in evaluating and translating fundamental results into clinical diabetes-associated ED. The concept of hard-to-treat patients, such as men with diabetes, is now fully accepted due to the complex mechanisms involved. In these men, the response to common oral treatments with phosphodiesterase type 5 inhibitors (PDE5Is) is far from desired, and maximal doses of the drugs are often needed. In addition, diabetes is commonly associated with other co-morbidities, such as hypertension, hypercholesterolaemia and obesity, clusters of the metabolic syndrome (MetS). ED is considered an early warning sentinel for coronary artery disease, just as endothelial dysfunction is seen as a major risk factor for ED. Testosterone deficiency syndrome, a very common syndrome in diabetes and MetS, has been shown to be an independent determinant of endothelial dysfunction, thus contributing to vascular pathology, including ED. This syndrome should be identified among patients, and therapeutic intervention may be required. PDE5Is may improve erectile function with or without the help of other second- or third-line treatments. Other strategies to maximise the response to PDE5Is include risk factor modification and daily dosing of the drugs, instead of on-demand treatment. However, better understanding of the fundamental molecular mechanisms underlying diabetes-associated ED is essential to improving and developing more effective therapies.
APA, Harvard, Vancouver, ISO, and other styles
20

Beach, Renee A., Frank Murphy, and Ronald B. Vender. "Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature." Journal of Cutaneous Medicine and Surgery 10, no. 3 (May 2006): 128–30. http://dx.doi.org/10.2310/7750.2006.00035.

Full text
Abstract:
Background: In the past 9 years, drugs for erectile dysfunction (ED) have been increasingly prescribed for men with erectile difficulty. These drugs, phosphodiesterase 5 (PDE5) inhibitors, help men with ED obtain and sustain an erection, improving both sexual function and sexual performance satisfaction. However, these drugs contain side effects. Objectives: A 56-year-old man developed an erythematous, circle-shaped lesion on his penis. The lesion was recurrent, with evidence of desquamation. The aim was to determine the source of the recurrent lesion based on its morphology and the patient's verbal history. Results: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made. He was not rechallenged with the drug. However, he experienced a subsequent recurrence of the eruption on inadvertent rechallenge. Conclusions: We believe this case to be the first report of this type of reaction owing to tadalafil. Therefore, fixed drug eruption is a newly observable side effect of this drug.
APA, Harvard, Vancouver, ISO, and other styles
21

Javaroni, Valter, and Mario Fritsch Neves. "Erectile Dysfunction and Hypertension: Impact on Cardiovascular Risk and Treatment." International Journal of Hypertension 2012 (2012): 1–11. http://dx.doi.org/10.1155/2012/627278.

Full text
Abstract:
Erectile dysfunction (ED) is a common complaint in hypertensive men and can represent a systemic vascular disease, an adverse effect of antihypertensive medication or a frequent concern that may impair drug compliance. ED has been considered an early marker of cardiovascular disease. The connection between both conditions seems to be located in the endothelium, which may become unable to generate the necessary dilatation in penile vascular bed in response to sexual excitement, producing persistent impairment in erection. On the other hand, the real influence of antihypertensive drugs in erectile function still deserves discussion. Therefore, regardless of ED mechanism in hypertension, early diagnosis and correct approach of sexual life represent an important step of cardiovascular evaluation which certainly contributes for a better choice of hypertension treatment, preventing some complications and restoring the quality of life.
APA, Harvard, Vancouver, ISO, and other styles
22

Dündar, Sema Oruç. "Editorial, Visual loss associated with erectile dysfunction drugs." Canadian Journal of Ophthalmology 42, no. 1 (2007): 10–12. http://dx.doi.org/10.3129/i06-122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

&NA;. "Antihyperlipidaemic drugs may be associated with erectile dysfunction." Reactions Weekly &NA;, no. 611 (July 1996): 4. http://dx.doi.org/10.2165/00128415-199606110-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Langford, Nigel. "Adverse reactions to drugs used for erectile dysfunction." Adverse Drug Reaction Bulletin 195, no. 1 (April 1999): 743–46. http://dx.doi.org/10.1097/00012995-199904000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Rasmussen, Lotte, Jesper Hallas, Kenneth Grønkjaer Madsen, and Anton Pottegård. "Cardiovascular drugs and erectile dysfunction - a symmetry analysis." British Journal of Clinical Pharmacology 80, no. 5 (July 28, 2015): 1219–23. http://dx.doi.org/10.1111/bcp.12696.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Peak, Taylor C., Faysal A. Yafi, Premsant Sangkum, and Wayne JG Hellstrom. "Emerging drugs for the treatment of erectile dysfunction." Expert Opinion on Emerging Drugs 20, no. 2 (March 5, 2015): 263–75. http://dx.doi.org/10.1517/14728214.2015.1021682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Gallé, G., and H. Trummer. "The etiology of erectile dysfunction and mechanisms by which drugs improve erection." Drugs of Today 39, no. 3 (2003): 193. http://dx.doi.org/10.1358/dot.2003.39.3.740216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Simonsen, U. "Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease." International Journal of Impotence Research 14, no. 3 (June 2002): 178–88. http://dx.doi.org/10.1038/sj.ijir.3900846.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Behr-Roussel, Delphine, Philippe Chamiot-Clerc, Jacques Bernabe, Katell Mevel, Laurent Alexandre, Michel E. Safar, and François Giuliano. "Erectile dysfunction in spontaneously hypertensive rats: pathophysiological mechanisms." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 284, no. 3 (March 1, 2003): R682—R688. http://dx.doi.org/10.1152/ajpregu.00349.2002.

Full text
Abstract:
Hypertensive men have a higher prevalence of erectile dysfunction (ED) than the general population. Experimental evidence of ED in hypertensive animals is scarce. This study evaluates the erectile function of spontaneously hypertensive rats (SHR) and age-matched normotensive Wistar-Kyoto rats (WKY) in vivo by the increase in intracavernosal pressure after electrical stimulation of the cavernous nerve (CN) and by isometric tension studies on corporal strips. Frequency-dependent erectile responses to CN stimulations were reduced in SHR. Phenylephrine induced lower corporal contractions in SHR although pD2 values were similar to WKY. Endothelium-dependent relaxations to ACh were impaired significantly in SHR, and indomethacin improved these relaxations in both WKY and SHR, the latter thus reaching values similar to WKY. Corporal relaxations to sodium nitroprusside were enhanced in SHR. Thus a dysfunctional α-adrenergic contraction of the corporal smooth muscle, an increased cyclooxygenase-dependent constrictor tone, and/or a defect in endothelium-dependent reactivity are associated with the altered erectile mechanisms in SHR. Drugs targeting endothelial dysfunction may delay the occurrence of ED as a complication of hypertension.
APA, Harvard, Vancouver, ISO, and other styles
30

Sutcliffe, Siobhan, Gerald L. Andriole, Ichiro Kawachi, Jonathan M. Zenilman, and Elizabeth A. Platz. "Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs." Annals of Internal Medicine 153, no. 8 (October 19, 2010): 549. http://dx.doi.org/10.7326/0003-4819-153-8-201010190-00020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Jena, Anupam B. "Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs." Annals of Internal Medicine 153, no. 8 (October 19, 2010): 550. http://dx.doi.org/10.7326/0003-4819-153-8-201010190-00021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Hornberg, J., H. Schneider, E. Brähler, A. Wirbatz, and W. Weidner. "179 ERECTILE DYSFUNCTION IN EPILEPTIC MEN WITH ANTIEPILEPTIC DRUGS." European Urology Supplements 9, no. 2 (April 2010): 88. http://dx.doi.org/10.1016/s1569-9056(10)60183-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

WORCESTER, SHARON. "STDs More Prevalent in Men on Erectile Dysfunction Drugs." Family Practice News 40, no. 14 (September 2010): 30. http://dx.doi.org/10.1016/s0300-7073(10)70901-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Kruger, Joshua M., and Howard D. Pomeranz. "Nonarteritic Anterior Ischemic Optic Neuropathy and Erectile Dysfunction Drugs." Journal of Neuro-Ophthalmology 37, no. 1 (March 2017): 104–5. http://dx.doi.org/10.1097/wno.0000000000000429.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Aversa, Antonio, Massimiliano Caprio, Giuseppe Rosano, and Giovanni Spera. "Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction." Current Pharmaceutical Design 14, no. 35 (December 1, 2008): 3768–78. http://dx.doi.org/10.2174/138161208786898725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Lee, Andrew G., and Nancy J. Newman. "Erectile Dysfunction Drugs and Nonarteritic Anterior Ischemic Optic Neuropathy." American Journal of Ophthalmology 140, no. 4 (October 2005): 707–8. http://dx.doi.org/10.1016/j.ajo.2005.07.055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Pavone, Carlo, Ninfa Giacalone, Marco Vella, Lidia Urso, Leila Zummo, and Brigida Fierro. "Relation between Sexual Dysfunctions and Epilepsy, Type of Epilepsy, Type of Antiepileptic Drugs: A Prospective Study." Urologia Journal 84, no. 2 (March 18, 2017): 88–92. http://dx.doi.org/10.5301/uro.5000222.

Full text
Abstract:
Introduction The aim of this study was to evaluate the incidence of sexual dysfunctions in males with epilepsy, the type of epilepsy, the frequency of seizures, the type of antiepileptic drugs (AEDs), the serum hormonal profile and the presence of psychiatric comorbidity. Methods Sixty-one patients focused on type of epilepsy, frequency of seizures, AEDs, hormonal profile and presence of mood disorders. We excluded all patients with severe neurologic and psychiatric impairment and patient who were not able to fill questionnaires. Mean age was 31.2 years (range 18-50 years); 31 patients (50.8%) had an idiopathic generalised epilepsy and 30 (49.2%) a focal epilepsy; among them, latter 18 (60%) had probably symptomatic type and 12 (40%) symptomatic type. Sexual functions were evaluated by “International Inventory of Erectile Function” questionnaire. Results Out of 61 enrolled patients, 22 (36.7%) showed sexual dysfunctions: erectile dysfunctions in 14 (23%), orgasmic dysfunctions in (11.5%) and sexual drive dysfunctions in 12 (19.7%). Out of 61 patients, 36 were subjected to blood measurement of sexual hormones and 21 (58.3%) showed hormonal modifications. Conclusions Sexual dysfunction are present in 36.7% of enrolled males with epilepsy; there is any association between sexual dysfunctions and various AEDs in the treatment, except for carbamazepine (CBZ); there is not any association between sexual dysfunctions and frequency of seizures; hormonal changes are associated with sexual dysfunction in males with epilepsy treated with AEDs but not with the orgasmic dysfunction; there is not any association between hormonal changes and type of AEDs, except for CBZ; depression is associated with sexual dysfunctions.
APA, Harvard, Vancouver, ISO, and other styles
38

Dastoli, Stefano, Luigi Francesco Iannone, Luigi Bennardo, Martina Silvestri, Caterina Palleria, Steven Paul Nisticò, Giovambattista De Sarro, and Emilio Russo. "A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report." Current Drug Safety 15, no. 1 (February 3, 2020): 69–72. http://dx.doi.org/10.2174/1574886314666190726155147.

Full text
Abstract:
Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.
APA, Harvard, Vancouver, ISO, and other styles
39

Dinsmore, W. W. "Patient-acquired hepatitis B and HIV following erectile dysfunction therapy." International Journal of STD & AIDS 16, no. 5 (May 1, 2005): 390–91. http://dx.doi.org/10.1258/0956462053888835.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Protogerou, Vassilis, Sara El Beshari, Efstathios Michalopoulos, Panagiotis Mallis, Dimosthenis Chrysikos, Alexandros A. Samolis, Catherine Stavropoulos-Giokas, and Theodoros Troupis. "The Combined Use of Stem Cells and Platelet Lysate Plasma for the Treatment of Erectile Dysfunction: A Pilot Study–6 Months Results." Medicines 7, no. 3 (March 18, 2020): 14. http://dx.doi.org/10.3390/medicines7030014.

Full text
Abstract:
Background: The current treatment of Erectile Dysfunction (ED) is mainly based on the use of drugs that provide erections shortly after use but they do not really treat the problem. Stem cell therapy is a novel treatment with regenerative properties that can possibly treat erectile dysfunction. Methods: Five patients with erectile disease were treated with Adipose-Derived Stem Cells (ADSCs) and Platelet Lysate Plasma (PLP). ADSCs were obtained through abdominal liposuction and PLP was prepared after obtaining blood samples from peripheral veins. Erectile function was evaluated with the International Index of Erectile Function questionnaire (IIEF-5) questionnaire, penile triplex at the 1st, 3rd, 6th and 12th month post-treatment. A CT scan of the head, thorax and abdomen was done before treatment and at the 12th month. Results: IIEF-5 scores were improved in all patients at the 6th month although not in the same pattern in all patients. Peak Systolic Velocity (PSV) also improved at the 6th month in all patients but also with different patterns in each patient, while End Diastolic Velocity (EDV) was more variable. Two patients decreased the treatment they used in order to obtain erection (from Intracavernosal injections (ICI) they used PDE-5Is), two had unassisted erections and one had an initial improvement which decreased at the 6th month. There were no side effects noted. Conclusions: Stem cell therapy in combination with PLP appears to show some improvement in erectile function and has minimal side effects in the short term.
APA, Harvard, Vancouver, ISO, and other styles
41

Alekseeva, Tatiana A., Alexander Yu Litvin, Eugenia M. Elfimova, Oxana O. Mikhailova, Vera N. Larina, Eugeny V. Shpot, Valery I. Podzolkov, and Irina E. Chazova. "Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction." Systemic Hypertension 18, no. 2 (July 5, 2021): 69–79. http://dx.doi.org/10.26442/2075082x.2021.2.200836.

Full text
Abstract:
Sexual health is an essential part of overall health, and an active and healthy sex life is an important aspect of a good quality of life. Cardiovascular diseases and sexual health disorders have common risk factors (arterial hypertension, diabetes mellitus, dyslipidemia, obesity and smoking) and common pathogenesis (endothelial dysfunction, inflammation and atherosclerosis). All this led to speculations about the pathophysiology and treatment options for sexual dysfunctions. The use of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction (ED) in men. This article focuses on ED and its relationship with hypertension. This document was created by experts from the Russian Medical Society of Arterial Hypertension with the participation of a member of the European Society of Hypertension Working Group on Sexual Dysfunction and Arterial Hypertension. In recent years, the expert group was very active in educating hypertension specialists and related specialties physicians about ED via numerous lectures at national and international congresses. It has been noted that ED precedes the development of coronary heart disease. The artery diameter hypothesis has been proposed as a possible explanation for this observation. Clinical manifestations of atherosclerotic lesions and/or endothelial dysfunction of the penile arteries may precede those in larger arteries. Patients with hypertension who receive antihypertensive drugs are more likely to suffer from sexual dysfunctions compared to untreated patients. The occurrence of ED appears to be related to the undesirable effects of antihypertensive drugs on the penile tissues. There is information about various effects of antihypertensive drugs on erectile function.
APA, Harvard, Vancouver, ISO, and other styles
42

Ghanem, Asaad Ghanem. "A Case of Recurrent Transient Monocular Visual Loss after Receiving Sildenafil." Case Reports in Ophthalmological Medicine 2011 (2011): 1–4. http://dx.doi.org/10.1155/2011/645089.

Full text
Abstract:
A 53-year-old man was attended to the Clinic Ophthalmic Center, Mansoura University, Egypt, with recurrent transient monocular visual loss after receiving sildenafil citrate (Viagra) for erectile dysfunction. Examination for possible risk factors revealed mild hypercholesterolemia. Family history showed that his father had suffered from bilateral nonarteritic anterior ischemic optic neuropathy (NAION). Physicians might look for arteriosclerotic risk factors and family history of NAION among predisposing risk factors before prescribing sildenafil erectile dysfunction drugs.
APA, Harvard, Vancouver, ISO, and other styles
43

Razdan, Shirin, Aubrey B. Greer, Amir Patel, Mahmoud Alameddine, Joshua S. Jue, and Ranjith Ramasamy. "Effect of prescription medications on erectile dysfunction." Postgraduate Medical Journal 94, no. 1109 (November 4, 2017): 171–78. http://dx.doi.org/10.1136/postgradmedj-2017-135233.

Full text
Abstract:
Erectile dysfunction (ED) affects about 50% of men in the USA and is primarily attributed to physiological (organic) and psychological causes. However, a substantial portion of men suffer from ED due to iatrogenic causes. Common medications such as antihypertensives, non-steroidal anti-inflammatory drugs and antacids may cause ED. Physicians should be aware of the various prescription medications that may cause ED to properly screen and counsel patients on an issue that many may feel too uncomfortable to discuss. In this review, we discuss the physiology, data and alternative therapies for the ED caused by medications.
APA, Harvard, Vancouver, ISO, and other styles
44

Aschenbrenner, Diane S. "REVISIONS TO THE LABELING OF ERECTILE DYSFUNCTION AND DIABETES DRUGS." AJN, American Journal of Nursing 108, no. 2 (February 2008): 79. http://dx.doi.org/10.1097/01.naj.0000310354.67108.6e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Shindel, A., S. Kishore, and T. Lue. "Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction." Current Pharmaceutical Design 14, no. 35 (December 1, 2008): 3758–67. http://dx.doi.org/10.2174/138161208786898752.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Barksdale, John D., and Stephanie F. Gardner. "The Impact of First-Line Antihypertensive Drugs on Erectile Dysfunction." Pharmacotherapy 19, no. 5 (May 1999): 573–81. http://dx.doi.org/10.1592/phco.19.8.573.31526.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Suppiah, Batumalai, Balasingam Vicknasingam, Darshan Singh, and Suresh Narayanan. "Erectile Dysfunction among People Who Use Ketamine and Poly-Drugs." Journal of Psychoactive Drugs 48, no. 2 (March 14, 2016): 86–92. http://dx.doi.org/10.1080/02791072.2016.1156790.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Hayreh, Sohan Singh. "Amiodarone, Erectile Dysfunction Drugs, and Non-Arteritic Ischemic Optic Neuropathy." Journal of Neuro-Ophthalmology 26, no. 2 (June 2006): 154–55. http://dx.doi.org/10.1097/01.wno.0000223279.55178.29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Khan, Masood A., Robert J. Morgan, and Dimitri P. Mikhailidis. "The Choice of Antihypertensive Drugs in Patients with Erectile Dysfunction." Current Medical Research and Opinion 18, no. 2 (January 2002): 103–7. http://dx.doi.org/10.1185/030079902125000426.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Rizvi, K. "Do lipid-lowering drugs cause erectile dysfunction? A systematic review." Family Practice 19, no. 1 (February 1, 2002): 95–98. http://dx.doi.org/10.1093/fampra/19.1.95.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography